Hypoglycemic effects of a beta-agonist, Ro 16-8714, in streptozotocin-diabetic rats: decreased hepatic glucose production and increased glucose utilization in oxidative muscles.
Streptozotocin (STZ)-induced diabetic rats are glycosuric, hyperglycemic, hyperketonemic, overproduce glucose, and have a decreased glucose utilization in oxidative muscles. Treatment with a beta-agonist, Ro 16-8714, decreases the glycosuria, hyperglycemia, hyperketonemia, and hepatic glucose production. Tissue glucose utilization was unchanged, except in oxidative muscles, where it was increased.
Ferré
P
P
Centre de Recherches sur la Nutrition (CNRS), Meudon, France.
Pénicaud
L
L
Hitier
Y
Y
Meier
M
M
Girard
J
J
D015078:2-Hydroxyphenethylamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D020155:3-Hydroxybutyric Acid; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000378:metabolism*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005947:Glucose / Q000378:metabolism*; D006029:Glycosuria; D006885:Hydroxybutyrates / Q000097:blood; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007700:Kinetics; D007773:Lactates / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D009132:Muscles / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values
D000318:Adrenergic beta-Agonists; D005230:Fatty Acids, Nonesterified; D006885:Hydroxybutyrates; D007004:Hypoglycemic Agents; D007773:Lactates; D015078:2-Hydroxyphenethylamine; C045606:4-(3-(bis(beta-hydroxyphenethyl)amino)butyl)benzamide; D005947:Glucose; D020155:3-Hydroxybutyric Acid